Aims/hypothesis Type 2 diabetes mellitus prevalence is increasing globally and the greatest
burden is borne by racialised people. However, there are concerns that the enrolment of …

Incretin hormones potentiate the glucose-induced insulin secretion following enteral nutrient
intake. The best characterised incretin hormones are glucagon-like peptide-1 (GLP-1) and …

Currently, there is no known cure for diabetes. Different pharmaceutical therapies have been
approved for the management of type 2 diabetes mellitus (T2DM), some are in clinical trials …

The discovery of long-acting incretin receptor agonists represents a major stride forward in
tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin …

Background: The aim of this study is to compare the effect of sodium–glucose cotransporter-
2 inhibitors (SGLT-2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl …

Bariatric surgery is rapidly gaining approval as a treatment for severe obesity, especially
when complicated by type 2 diabetes. In Centers of Excellence, postoperative care is usually …

Background: Obesity affects many patients with inflammatory bowel disease (IBD). Glucagon-
like peptide (GLP)-1 agonists are a promising therapy for obese patients. However, there is …

抄録 Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor
agonists, called incretin modulators, are key drugs for managing type 2 diabetes that are …